Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN057 injection for long-term prophylaxis in hemophilia A or B with or without inhibitors
CTR20255089Phase 3Active
- Sponsor
- Alphamab Oncology
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Armocibart in hemophilia A, hemophilia B (HB), sponsored by Alphamab Oncology. Started Mar 2026; status: active.
02
Drugs
Armocibart
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20255089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255089.